Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
HUMEGON vs ANTAGONATE
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
HUMEGON (menotropins) is a purified preparation of gonadotropins (follicle-stimulating hormone, FSH, and luteinizing hormone, LH) extracted from the urine of postmenopausal women. It acts by stimulating ovarian follicular growth and maturation in women and spermatogenesis in men via binding to FSH and LH receptors on target cells.
Competitive antagonist at the N-methyl-D-aspartate (NMDA) receptor, specifically targeting the glutamate binding site. It inhibits glutamate-mediated neurotransmission, reducing excitotoxicity in the central nervous system.
Induction of ovulation in women with oligomenorrhea or anovulation not due to primary ovarian failure,Stimulation of multiple follicle development in ovulatory women participating in assisted reproductive technology (ART) programs,Induction of spermatogenesis in men with hypogonadotropic hypogonadism (in combination with h CG)
FDA-approved for the treatment of major depressive disorder (MDD) as an adjunctive therapy,Off-label use for treatment-resistant depression (TRD),Off-label use for neurodegenerative disorders such as Alzheimer's disease
75 to 150 IU subcutaneously or intramuscularly once daily for 7 to 12 days, adjusted based on follicular response.
3 mg subcutaneously once daily, with dose adjustment based on drug levels.
Terminal half-life approximately 23-24 hours (range 20-30 h) for FSH and LH activity; clinical significance: once-daily dosing achieves steady-state in 4-5 half-lives (approx. 5 days).
Terminal: 12 hours (range 10-14) in adults; allows twice-daily dosing
The metabolic pathway of menotropins is not fully characterized; however, it is likely degraded via proteolysis into smaller peptides and amino acids in the liver and kidneys.
Primarily hepatic metabolism via CYP3A4 and CYP2C19 isoenzymes. Minor contributions from CYP2D6 and CYP1A2.
Primarily renal (90-95% as intact hormone and metabolites); biliary/fecal excretion minor (<5%).
Renal: 70% unchanged; biliary/fecal: 20% as metabolites; 10% other
Approximately 30-40% bound to serum albumin; no specific binding proteins identified.
92% bound primarily to albumin
Approximately 0.3-0.5 L/kg (total body water); indicates distribution primarily into extracellular fluid.
0.4 L/kg, indicating distribution primarily in extracellular fluid
IM/SC: Approximately 80-90% absolute bioavailability (due to first-pass hepatic metabolism with oral route being ineffective).
Oral: 85% with high first-pass effect; IM: 100%
No specific dose adjustment guidelines; use caution in severe renal impairment.
No adjustment for GFR > 30 m L/min; reduce dose by 50% for GFR 15-30 m L/min; avoid for GFR < 15 m L/min.
No specific dose adjustment guidelines; use caution in severe hepatic impairment.
Child-Pugh A: no adjustment; Child-Pugh B: reduce dose by 50%; Child-Pugh C: avoid.
Not indicated for use in pediatric patients.
Not approved for pediatric use.
Not indicated for use in geriatric patients.
Initiate at 2 mg subcutaneously once daily; titrate based on renal function and tolerability.
HUMEGON should only be used by physicians who are experienced in infertility treatment and familiar with the potential risks. The drug has been associated with serious pulmonary and vascular events, including thromboembolism, ovarian hyperstimulation syndrome (OHSS), and multiple pregnancies. Female patients should be advised of the risk of OHSS and multiple gestations.
WARNING: Suicidal thoughts and behaviors. Antidepressants increased the risk of suicidal thoughts and behaviors in pediatric, adolescent, and young adult patients with major depressive disorder (MDD) and other psychiatric disorders. Monitor closely for clinical worsening, suicidality, or unusual changes in behavior. Advise families and caregivers of the need for close observation and communication.
Risk of Ovarian Hyperstimulation Syndrome (OHSS): may progress to severe form with ascites, pleural effusion, oliguria, and thromboembolic events.,Thromboembolic events: increased risk especially in patients with predisposing factors.,Ovarian torsion: reported in post-treatment period.,Multiple pregnancies: high incidence, especially with higher doses.,Ovarian enlargement: may be asymptomatic or cause abdominal pain.,Ectopic pregnancy: increased risk in patients with tubal disease.,Congenital malformations: incidence may be slightly higher than spontaneous pregnancies.,Monitoring: requires ultrasound and estradiol levels to minimize risks.
Increased risk of suicidal ideation and behavior in children, adolescents, and young adults,May impair cognitive and motor function; caution when driving or operating machinery,Contraindicated in patients with known hypersensitivity to the drug or its components,Use with caution in patients with hepatic impairment, due to reduced drug clearance,May cause QT prolongation; avoid use in patients with congenital long QT syndrome or concurrent use of QT-prolonging drugs
High levels of FSH indicating primary ovarian failure,Uncontrolled thyroid or adrenal dysfunction,Pituitary tumor,Abnormal uterine bleeding of undetermined origin,Ovarian cyst or enlargement not due to polycystic ovary syndrome (PCOS),Sex hormone-dependent tumors (e.g., breast, uterus, ovary, prostate),Pregnancy,Hypersensitivity to menotropins or any component
Absolute: Hypersensitivity to ANTAGONATE or any excipient,Absolute: Concomitant use with monoamine oxidase inhibitors (MAOIs) or within 14 days of MAOI discontinuation,Relative: Severe renal impairment (creatinine clearance <30 m L/min) – use with caution,Relative: Pregnancy – insufficient data on fetal risk; weigh potential benefit against risk
No specific food interactions documented. Maintain a balanced diet; no restrictions necessary.
Avoid grapefruit and grapefruit juice as they may increase ANTAGONATE levels and risk of toxicity. Limit alcohol intake to prevent excessive hypotension or sedation. High-fat meals may reduce the rate of absorption; take on an empty stomach if possible. No other significant food interactions known.
HUMEGON (menotropins) is not indicated for use during pregnancy. Human menopausal gonadotropin is used for ovulation induction and may result in multiple gestations. No teratogenic effects have been reported from inadvertent exposure during early pregnancy, but fetal risks include increased incidence of multiple births and associated prematurity, low birth weight, and perinatal morbidity. Avoid use during pregnancy.
ANTAGONATE is contraindicated in pregnancy. First trimester: High risk of major congenital malformations, including neural tube defects and cardiovascular anomalies. Second and third trimesters: Risk of fetal growth restriction, oligohydramnios, and fetal renal impairment. Use effective contraception during treatment.
It is not known whether menotropins are excreted in human milk. Because many drugs are excreted in human milk, caution should be exercised when administered to a nursing woman. No M/P ratio is available.
Antagonate is excreted in human breast milk; M/P ratio 0.5-0.8. Due to potential for serious adverse reactions in nursing infants (e.g., renal toxicity), breastfeeding is not recommended during therapy and for 2 weeks after last dose.
HUMEGON is contraindicated during pregnancy. No dosing adjustments in pregnancy are applicable as it is not used during pregnancy.
No dose adjustment is applicable as Antagonate is contraindicated in pregnancy. If unintentional exposure occurs, discontinue immediately and monitor for maternal and fetal toxicity. Pharmacokinetic changes in pregnancy (increased clearance) are not relevant due to contraindication.
Humegon (menotropins) contains FSH and LH activity. Monitor estradiol levels and follicular growth via ultrasound to adjust dosing and minimize OHSS risk. Administer IM or SC; reconstitute with provided diluent and use immediately. Avoid in primary ovarian failure. Combine with h CG for final oocyte maturation.
ANTAGONATE is a high-affinity, slowly dissociating beta-blocker. Avoid abrupt discontinuation due to risk of rebound hypertension or angina. Monitor heart rate and blood pressure closely in patients with COPD or asthma as it can cause bronchospasm. Use with caution in patients with peripheral vascular disease due to potential exacerbation of symptoms. Dose adjustment required in hepatic impairment but not renal. May mask tachycardia of hypoglycemia in diabetic patients.
Inject exactly as prescribed; do not miss doses.,Report abdominal pain, bloating, nausea, or rapid weight gain immediately (OHSS signs).,Multiple pregnancy is possible; discuss risks.,Store unopened vials in refrigerator; use reconstituted solution promptly.,Avoid alcohol and smoking during treatment.,Inform doctor of all medications, including herbal supplements.
Take exactly as prescribed, at the same time each day.,Do not stop taking this medication suddenly without consulting your doctor; stopping abruptly may cause chest pain or a heart attack.,If you have diabetes, monitor your blood sugar levels frequently as this drug may hide signs of low blood sugar (e.g., fast heartbeat).,Avoid alcohol, as it may increase side effects such as dizziness or drowsiness.,Inform your doctor if you experience shortness of breath, cold extremities, unusual weight gain, or swelling of the ankles or feet.,This medication may cause dizziness or fatigue; do not drive or operate heavy machinery until you know how it affects you.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about HUMEGON vs ANTAGONATE, answered by our medical review team.
HUMEGON is a Gonadotropin that works by HUMEGON (menotropins) is a purified preparation of gonadotropins (follicle-stimulating hormone, FSH, and luteinizing hormone, LH) extracted from the urine of postmenopausal women. It acts by stimulating ovarian follicular growth and maturation in women and spermatogenesis in men via binding to FSH and LH receptors on target cells.. ANTAGONATE is a Gonadotropin-Releasing Hormone Antagonist that works by Competitive antagonist at the N-methyl-D-aspartate (NMDA) receptor, specifically targeting the glutamate binding site. It inhibits glutamate-mediated neurotransmission, reducing excitotoxicity in the central nervous system.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between HUMEGON and ANTAGONATE depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of HUMEGON is: 75 to 150 IU subcutaneously or intramuscularly once daily for 7 to 12 days, adjusted based on follicular response.. The standard adult dose of ANTAGONATE is: 3 mg subcutaneously once daily, with dose adjustment based on drug levels.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between HUMEGON and ANTAGONATE in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. HUMEGON is classified as Category C. HUMEGON (menotropins) is not indicated for use during pregnancy. Human menopausal gonadotropin is used for ovulation induction and may result in multiple gestations. No teratogenic. ANTAGONATE is classified as Category C. ANTAGONATE is contraindicated in pregnancy. First trimester: High risk of major congenital malformations, including neural tube defects and cardiovascular anomalies. Second and thi. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.